Taysha Gene Therapies (TSHA) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Taysha Gene Therapies (TSHA) is Neutral.

The composite score behind that read is -0.06, weighing +0.10 of bullish evidence against -0.25 bearish.

Taysha Gene Therapies last closed at $4.49, +1.35% on the session.

Against the IVW growth benchmark the position is +0.55% over the forecast window.

The read is built from 15 underlying insights — 5 bullish and 10 bearish.

Agreement across those insights is 67%.

Taysha Gene Therapies has no graded predictions yet. We publish our accuracy across thousands of stocks in the open, misses included.

On the fundamentals StockMap ranks Taysha Gene Therapies in the 17th percentile on return on equity, where 100 is best.

Taysha Gene Therapies is classified under Health Care / Biotechnology, with a market capitalisation of $1.44B.

StockMap tracks Taysha Gene Therapies as the 112th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Taysha Gene Therapies ranks 180th of 381 in the group, against a group median of -0.08.